Esteve Pharmaceuticals, S.A.
Records under this name other than the patents Esteve Pharmaceuticals, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 35 patents it holds.
Back to Esteve Pharmaceuticals, S.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,988,425 | Immunogens for HIV Vaccination Formerly held In force · High confidence | In force | High confidence | |
| US 10,815,278 | Immunogens for HIV Vaccination Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,919,926 | Method of Treating HIV-1 Infection Utilizing a Multiepitope T Cell Immunogen Comprising Gag, Pol, Vif, and Nef Epitopes Formerly held In force · High confidence | In force | High confidence | |
| US 11,013,729 | Oral Pharmaceutical Compositions of Dabigatran Etexilate Formerly held In force · High confidence | In force | High confidence | |
| US 11,325,946 | Method of Treating HIV-1 Infection Utilizing a Multiepitope T Cell Immunogen Comprising Gag, Pol, Vif and Nef Epitopes Formerly held In force · High confidence | In force | High confidence | |
| US 10,246,465 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,146,169 | Adenoassociated Virus Vectors for the Treatment of Mucopolysaccharidoses Type IV A Formerly held In force · High confidence | In force | High confidence | |
| US 12,398,403 | Methods for the Manufacture of Recombinant Viral Vectors Formerly held In force · High confidence | In force | High confidence | |
| US 11,401,270 | New Alcoxyamino Derivatives for Treating Pain and Pain Related Conditions Lapsed on the fee record Ended Aug 2, 2026 · High confidence | Lapsed on the fee record | Ended Aug 2, 2026 | High confidence |
| US 11,338,046 | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses Lapsed on the fee record Ended May 24, 2026 · USPTO record | Lapsed on the fee record | Ended May 24, 2026 | USPTO record |